Comparative efficacy and tolerability of paliperidone palmitate and risperidone long–term injection

Abstract

A new long–term injection antipsychotic, paliperidone palmitate (Xeplion), has appeared in 2011 year in Russia. Paliperidone (9 hydroxyrisperidone) is a metabolite molecule of risperidone, which is an evident analogue to well–known long–term injection antipsychotic drug Rispolept Consta (long–term injection risperidone). There are technical differences between products, which makes it possible to use monthly injections in paliperidone palmitate instead of once in 2 weeks injections of long–term risperidone. To receive comprehensive clinical data on new product, the analysis of paliperidone palmitate clinical trilas` results were arranged. The following review includes publications from Cochrane register, dedicated to studies of paliperidone palmitate efficacy, safety and tolerability, including its comparison to other antipsychotic drugs.